methyl-4-(adenin-9-yl)-2-hydroxybutanoate and Disease-Models--Animal

methyl-4-(adenin-9-yl)-2-hydroxybutanoate has been researched along with Disease-Models--Animal* in 3 studies

Other Studies

3 other study(ies) available for methyl-4-(adenin-9-yl)-2-hydroxybutanoate and Disease-Models--Animal

ArticleYear
DZ2002 alleviates psoriasis-like skin lesions via differentially regulating methylation of GATA3 and LCN2 promoters.
    International immunopharmacology, 2021, Volume: 91

    Psoriasis is the most prevalent inflammatory skin disorders, affecting 1-3% of the worldwide population. We previously reported that topical application of methyl 4-(adenin-9-yl)-2-hydroxybutanoate (DZ2002), a reversible S-adenosyl-l-homocysteine hydrolase (SAHH) inhibitor, was a viable treatment in murine psoriatic skin inflammation. In current study, we further explored the mechanisms of DZ2002 on keratinocyte dysfunction and skin infiltration, the key pathogenic events in psoriasis. We conducted genome-wide DNA methylation analysis in skin tissue from imiquimod (IMQ)-induced psoriatic and normal mice, demonstrated that topical administration of DZ2002 directly rectified aberrant DNA methylation pattern in epidermis and dermis of psoriatic skin lesion. Especially, DZ2002 differentially regulated DNA methylation of GATA3 and LCN2 promoters, which maintained keratinocytes differentiation and reduced inflammatory infiltration in psoriatic skin respectively. In vitro studies in TNF-α/IFN-γ-elicited HaCaT manifested that DZ2002 treatment rectified compromised keratinocyte differentiation via GATA3 enhancement and abated chemokine expression by reducing LCN2 production under inflammatory stimulation. Chemotaxis assays conducted on dHL-60 cells confirmed that suppression of LCN2 expression by DZ2002 was accompanied by CXCR1 and CXCR2 downregulation, and contributed to the inhibition of CXCL8-driven neutrophils migration. In conclusion, therapeutic benefits of DZ2002 are achieved through differentially regulating DNA methylation of GATA3 and LCN2 promoters in psoriatic skin lesion, which efficiently interrupt the pathogenic interplay between keratinocytes and infiltrating immune cells, thus maintains epidermal keratinocytes differentiation and prevents dermal immune infiltration in psoriatic skin.

    Topics: Adenine; Animals; Anti-Inflammatory Agents; Butyrates; Cell Differentiation; Cell Proliferation; Chemokines; Disease Models, Animal; DNA Methylation; Female; GATA3 Transcription Factor; HaCaT Cells; HL-60 Cells; Humans; Keratinocytes; Lipocalin-2; Mice, Inbred BALB C; Neutrophil Infiltration; Promoter Regions, Genetic; Psoriasis; Skin

2021
DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models.
    Arthritis research & therapy, 2019, 12-16, Volume: 21, Issue:1

    Systemic sclerosis is a multisystem inflammatory and vascular lesion leading to extensive tissue fibrosis. A reversible S-adenosyl-l-homocysteine hydrolase (SAHH) inhibitor, DZ2002, modulates the pathologic processes of various inflammatory diseases and autoimmune diseases. This study is designed to investigate the therapeutic potentiality of DZ2002 for experimental systemic sclerosis models.. The anti-inflammatory and anti-fibrotic features of DZ2002 and its mechanisms were investigated in a bleomycin (BLM)-induced dermal fibrosis mice model. The effects of DZ2002 on expression of extracellular matrix components and TGF-β signaling in human dermal fibroblasts were analyzed. Simultaneously, the effects of DZ2002 on macrophage activation and endothelial cell adhesion molecule expression were also evaluated.. DZ2002 significantly attenuated dermal fibrosis in BLM-induced mice. Consistently, DZ2002 inhibited the expression of various molecules associated with dermal fibrosis, including transforming growth factor β1, connective tissue growth factor, tumor necrosis factor-α, interferon-γ, IL-1β, IL-4, IL-6, IL-10, IL-12p40, IL-17A, and monocyte chemotactic protein 1 in the lesional skin of BLM-induced mice. Furthermore, DZ2002 decreased the proportion of macrophages, neutrophils, and T cells (especially T helper cells) in the skin tissue of BLM-induced mice. In addition, DZ2002 attenuated both M1 macrophage and M2 macrophage differentiation in vivo and in vitro. Importantly, DZ2002 directly reversed the profibrotic phenotype of transforming growth factor-β1-treated dermal fibroblasts and suppressed ICAM-1, VCAM-1, VEGF, bFGF, and ET-1 expression in endothelial cells. Finally, our investigations showed that DZ2002 relieved systemic sclerosis by regulating fibrosis TGF-β/Smad signaling pathway.. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types and would be a potential drug for the treatment of systemic sclerosis.

    Topics: Adenine; Animals; Bleomycin; Butyrates; Cell Line; Cells, Cultured; Dermis; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Gene Expression; Humans; Inflammation; Macrophages; Mice, Inbred C57BL; Scleroderma, Systemic; THP-1 Cells; Transforming Growth Factor beta; Vascular Diseases; Vascular Endothelial Growth Factor A

2019
Critical role of transmethylation in TLR signaling and systemic lupus erythematosus.
    Clinical immunology (Orlando, Fla.), 2013, Volume: 147, Issue:2

    Post-translational protein modifications can play a significant role in immune cell signaling. Recently, we showed that inhibition of transmethylation curtails experimental autoimmune encephalomyelitis, notably by reducing T cell receptor (TCR)-induced activation of CD4(+) T cells. Here, we demonstrate that transmethylation inhibition by a reversible S-adenosyl-l-homocysteine hydrolase inhibitor (DZ2002) led to immunosuppression by reducing TLR-, B cell receptor (BCR)- and TCR-induced activation of immune cells, most likely by blocking NF-κB activity. Moreover, prophylactic treatment with DZ2002 prevented lupus-like disease from developing in both BXSB and MRL-Fas(lpr) mouse models. DZ2002 treatment initiated during active disease significantly improved outcomes in both in vivo models, suggesting methylation inhibition as a novel approach for the treatment of autoimmune/inflammatory diseases.

    Topics: Adenine; Animals; Antigen-Presenting Cells; Autoantibodies; B-Lymphocytes; Butyrates; CD4-Positive T-Lymphocytes; Cytokines; Disease Models, Animal; Female; Immunoglobulin G; Immunosuppressive Agents; Kidney; Lupus Erythematosus, Systemic; Male; Methylation; Mice; Mice, Inbred C57BL; Mice, Transgenic; NF-kappa B; Protein Processing, Post-Translational; Signal Transduction; Toll-Like Receptors

2013